The most important idea: set and setting
The single best-supported principle in this entire field is that the molecule is only half the story. Set (your mindset, intention, and emotional state) and setting (your physical and social surroundings) are not soft add-ons. They are primary determinants of whether an experience heals or harms.
The traditions understood this long before science did. The Mazatec velada, the Amazonian ayahuasca ceremony, and the Bwiti iboga initiation are each a whole container: music, guidance, safety and meaning around the substance. A recent analysis of clinical data even found that the therapeutic relationship works indirectly: a strong, trusting container doesn't heal on its own. It makes a meaningful experience possible, and that experience is what carries the benefit (Goodwin et al., 2026).
The interactions that matter
Ayahuasca + antidepressants (SSRIs/SNRIs)
SeriousAyahuasca works precisely because it contains an MAO inhibitor (the beta-carbolines that let DMT survive digestion). Combining an MAO inhibitor with common antidepressants (SSRIs and SNRIs) risks serotonin syndrome, a potentially life-threatening reaction. This is the clearest, best-established danger in the whole family, and the pharmacological basis for the warnings every reputable ceremony gives.
Iboga and ibogaine: the heart
SeriousIbogaine can disturb the heart's rhythm (it prolongs the QT interval), and this cardiac risk is real and has caused deaths. Serious clinical programs use it only with cardiac screening and monitoring, the 2024 Nature Medicine veterans study paired it with magnesium specifically to protect the heart. This is never a casual, unsupervised substance.
A vulnerability to psychosis
Research screens for itFor a person with a personal or strong family history of psychosis or bipolar disorder, classic psychedelics can be genuinely risky. Reputable research screens carefully for exactly this. The physical toxicity of psilocybin is very low, but "low physical risk" is not the same as "no risk," and the real hazards here are psychological.
Dose: the quiet problem
Dose is the least measurable variable in unsupervised use, because the material itself is not standardised. Mushroom potency varies many-fold between samples, and the name on the jar is a weak predictor of strength. The randomised evidence in depression comes from supervised clinical trials using full single doses, while microdosing has repeatedly not separated from placebo in controlled trials of mood, cognition, and creativity. Whether a whole mushroom differs in effect from an equal quantity of isolated psilocybin is an open question in the chemistry, and our book sets out the evidence for and against. What is measured, rather than hypothesised, is that the tryptamine content of mushroom material varies widely between and within strains.
The part everyone skips: integration
The evidence increasingly suggests that these substances open a temporary window of neuroplasticity, a period when the brain is unusually ready to form new patterns. Researchers increasingly treat the period after a session as part of the intervention rather than an epilogue, and clinical protocols build structured integration sessions into the design. How much of any durable change depends on that work, and what form of it helps, has not been tested directly in healthy adults. Integration is the part of the field where the open questions are largest.